➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Colorcon
Moodys
Boehringer Ingelheim
Merck
Express Scripts

Last Updated: September 26, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CYMBALTA

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for CYMBALTA

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00105989 Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder Completed Boehringer Ingelheim Phase 3 2005-03-01 The purpose of this study is to assess the efficacy and safety of duloxetine compared with placebo in the prevention of depressive recurrences among patients with recurrent major depressive disorder.
NCT00105989 Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder Completed Eli Lilly and Company Phase 3 2005-03-01 The purpose of this study is to assess the efficacy and safety of duloxetine compared with placebo in the prevention of depressive recurrences among patients with recurrent major depressive disorder.
NCT00114127 Duloxetine for Social Anxiety Disorder: Prediction of Long Term Outcome Completed Massachusetts General Hospital Phase 3 2004-06-01 The purpose of this study is to examine the safety and efficacy of duloxetine for the treatment of social anxiety disorder.
NCT00177671 Antidepressant Medication Plus Donepezil for Treating Late-life Depression Completed National Institute of Mental Health (NIMH) Phase 4 2003-12-01 This study will determine the effectiveness of combining escitalopram, venlafaxine, or duloxetine with donepezil, a medication used in Alzheimer's disease, in improving memory, concentration, attention, and problem solving abilities, and reducing the risk of depressive relapse in older individuals with depression.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for CYMBALTA

Condition Name

Condition Name for CYMBALTA
Intervention Trials
Major Depressive Disorder 18
Depression 14
Fibromyalgia 8
Generalized Anxiety Disorder 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for CYMBALTA
Intervention Trials
Depression 41
Depressive Disorder 38
Depressive Disorder, Major 27
Disease 23
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for CYMBALTA

Trials by Country

Trials by Country for CYMBALTA
Location Trials
United States 408
Canada 27
United Kingdom 11
Germany 10
Australia 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for CYMBALTA
Location Trials
New York 24
California 22
Florida 21
Ohio 21
Texas 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for CYMBALTA

Clinical Trial Phase

Clinical Trial Phase for CYMBALTA
Clinical Trial Phase Trials
Phase 4 47
Phase 3 33
Phase 2/Phase 3 3
[disabled in preview] 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for CYMBALTA
Clinical Trial Phase Trials
Completed 75
Recruiting 19
Not yet recruiting 9
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for CYMBALTA

Sponsor Name

Sponsor Name for CYMBALTA
Sponsor Trials
Eli Lilly and Company 58
Shionogi 7
Boehringer Ingelheim 7
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for CYMBALTA
Sponsor Trials
Industry 86
Other 83
NIH 9
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKinsey
Dow
Express Scripts
Harvard Business School
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.